- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05395286
Innovation Labs to Enhance Collaboration
24 de mayo de 2022 actualizado por: Larry Hawk, Ph.D., State University of New York at Buffalo
Controlled Evaluation of Innovation Labs for Enhancing Collaboration Among Early Career Scholars in the CTSA Network
We will conduct and evaluate the impact of two week-long Innovation Labs on collaboration attitudes and behavior among early career scholars.
Applicants to each Innovation Lab will be screened and then randomized to either the Innovation Lab group or a control group.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Building on the science of team science and preliminary work at the Buffalo and Vanderbilt CTSAs, we propose to work with our industry partner Knowinnovation to implement, assess, and disseminate an innovative and promising method for stimulating and nurturing new transdisciplinary research teams across the CTSA Program consortium: Innovation Labs.
We will focus on early career investigators, have well-developed expertise, and will benefit from developing transdisciplinary collaborations.
This work will further advance the field by taking a strong translational science approach to identify and test "best practices".
To accomplish this, we will critically evaluate the impact of Innovation Labs in two preliminary randomized controlled trials (RCTs).
In collaboration with NCATs and broad input from the CTSA network, we will develop a clinical and translational research grand challenge focus for each Innovation Lab.
A diverse applicant pool of early career investigators invited from every CTSA hub in the consortium will be reviewed, and top applicants will be randomized to a 5-day residential Innovation Lab or "treatment as usual" control group (n=25/group/RCT).
Measures of process and outcome will be collected from the application phase through 12-month follow-up and aggregated across the two RCTs.
Given the preliminary nature of the work and an emerging consensus regarding the science of team science, primary outcomes will be measures of the depth and breadth of participants collaborative networks and attitudes towards collaboration, which we predict will be enhanced in the Innovation Lab group compared to the treatment as usual control group.
We will also gather initial data on the degree to which Innovation Labs result in increased transdisciplinary collaborative output, including grant proposals, publications, and presentations.
The significance of this work is clear: We aim to advance clinical and translational science by critically evaluating a potential "best practice" method for catalyzing collaborations and enhancing innovative translational research, a core goal of the CTSA Program.
Our initial RCTs target an important segment of the workforce and begin the process of dissemination across the CTSA network, setting the stage for much broader implementation and impact.
Tipo de estudio
Intervencionista
Inscripción (Actual)
94
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
New York
-
Buffalo, New York, Estados Unidos, 14260
- University at Buffalo
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
Completion of application and baseline assessment.
For randomization:
- Faculty at a NIH CTSA hub institution or regional partner.
- Early stage investigators (NIH-defined as "within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)") who are emerging as independent scholars.
- Applications were reviewed for the above criteria and ranked by committee according to goodness of fit with the topic of the Innovation Lab, the quality and quantity of academic productivity and collaboration, and contribution to diversity of perspectives among Lab participants (e.g., biomedical and social/psychological, basic and applied). Top-ranked applicants were retained for randomization to the Innovation Lab group or control group.
All applicants (including 94 randomized ppts and 13 ppts who were not randomized) were encouraged to remain in the study and complete the follow-up assessments.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Innovation Lab Group
Randomized to attend the Innovation Lab
|
An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge.
Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
|
Sin intervención: Control Group
Randomized to NOT attend the Innovation Lab
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from Baseline MATRICx Benefits Scale
Periodo de tiempo: through study completion, an average of 15 months
|
Self-report: Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) - Motivator scale
|
through study completion, an average of 15 months
|
Change from Baseline MATRICx Threats Scale
Periodo de tiempo: through study completion, an average of 15 months
|
Self-report: Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) - Threats scale
|
through study completion, an average of 15 months
|
Change from Baseline Transdisciplinary Orientation Scale
Periodo de tiempo: through study completion, an average of 15 months
|
Self-report: 12-item Transdisciplinary Orientation scale (TDO; Misra, Stokols, & Cheng, 2015)
|
through study completion, an average of 15 months
|
Change from Baseline Collaboration Network Size
Periodo de tiempo: through study completion, an average of 15 months
|
Objective size of network of collaborators from published articles on PubMed
|
through study completion, an average of 15 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from Baseline Grants Submitted
Periodo de tiempo: through study completion, an average of 15 months
|
Self-Reported Number of New Grants Submitted
|
through study completion, an average of 15 months
|
ILab met goal - new collab
Periodo de tiempo: 3 months
|
The Lab met the goal of forming new transdisciplinary collaborations (ILab group only)
|
3 months
|
ILab met goal - novel proposals
Periodo de tiempo: 3 months
|
The Lab met the goal of developing novel grant proposals on long-lasting lifestyle interventions (ILab group only)
|
3 months
|
ILab - recommend
Periodo de tiempo: 3 months
|
I would recommend an Innovation Lab to a colleague (ILab group only)
|
3 months
|
ILab - positive impact
Periodo de tiempo: 3 months
|
My experience in the Innovation Lab will have a positive impact on my work at my home institution (ILab group only)
|
3 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
3 de agosto de 2017
Finalización primaria (Actual)
12 de julio de 2019
Finalización del estudio (Actual)
25 de junio de 2020
Fechas de registro del estudio
Enviado por primera vez
19 de mayo de 2022
Primero enviado que cumplió con los criterios de control de calidad
24 de mayo de 2022
Publicado por primera vez (Actual)
27 de mayo de 2022
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
27 de mayo de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
24 de mayo de 2022
Última verificación
1 de mayo de 2022
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- STUDY00001360
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Innovation Lab
-
Medipol UniversityAún no reclutando
-
Sunmi SongReclutamientoDolor crónico | Depresión en la vejez | Trastorno del sueño Insomnio CrónicoCorea, república de
-
Istanbul UniversityReclutamiento
-
ImmunexpressRhode Island HospitalTerminadoSepticemia | SEÑORESEstados Unidos
-
Tatch Inc.Aún no reclutandoSíndromes de apnea del sueño | Apnea del sueño | Síndromes de apnea del sueño en niñosEstados Unidos
-
SunWay Biotech Co., LTD.TerminadoMicrobioma gastrointestinalTaiwán
-
SunWay Biotech Co., LTD.National Taiwan University Hospital; Chung Shan Medical UniversityTerminado
-
University of Electronic Science and Technology...TerminadoActividad de la ínsula anterior durante la regulación | Respuestas empáticas después de la regulación de la ínsula anterior
-
University Hospital, GenevaBioMérieuxTerminadoFiebre Sin OrigenSuiza
-
Cliniques universitaires Saint-Luc- Université...TerminadoSaludable | Fibrosis quísticaBélgica